? The specific goals for Core C are:? 1) establishment of lymphoblastoid cell lines and fibroblast cultures on LFS and WT patients.? 2) isolation of DNA, RNA, and plasma from peripheral blood; and DNA and RNA from tumor and normal? tissue samples from study individuals. This includes those with Wilms tumors, those who are? potential p53 mutation carriers, and family members of these individuals.? 3) mutation detection by direct sequencing of PCR products for p53, WT1, and/or some WT """"""""pathway""""""""? genes for childhood sarcoma kindreds, Wilms tumor kindreds, and sporadic Wilms tumors? 4) Southern analysis of WT patients to identify WT1 deletions undetectable by PCR-based sequencing.? 5) functional characterization of odd p53 missense mutations and identification of potentially truncated? proteins in cells from individuals carrying nonsense and splicing mutants? 6) mutation screening by WAVE analysis for selected WT pathway genes identified in Project 4? 7) storage and distribution, as needed, of DNA, RNA, and plasma samples? 8) maintenance of a database detailing sample handling, nucleic acids isolations, and mutational? analysis. This database will be used to update the Program's database managed by Core C.? 9) archiving of sequence and mutation screening output.? These functions are critical to the success of all projects within the P01. Project 1 uses p53 and WT1 data? to characterize better cancer risk and also to develop better genetic models for cancer predisposition. The? information regarding p53 mutational status will also identify non-p53 families that will aid the identification? (Proj. 2) of other genes responsible for predisposition and guide the interpretation of the tumor data? generated from mutant mice (Projects 3 & 5). WT1 mutational status is critical for the delineation of the? molecular subsets of Wilms tumors and WT patients and elucidating the biologic effect of the pattern of? mutations, alterations, and expression changes we have previously identified in Wilms tumors (Project 4).? This core provides sample processing, mutation screening and analyses, functional analyses, sample? storage, and data storage critical for all projects of the P01.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA034936-19A2
Application #
7118393
Study Section
Subcommittee G - Education (NCI)
Project Start
2006-04-01
Project End
2011-04-30
Budget Start
2006-06-19
Budget End
2007-04-30
Support Year
19
Fiscal Year
2006
Total Cost
$156,455
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Peng, Gang; Bojadzieva, Jasmina; Ballinger, Mandy L et al. (2017) Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO. Cancer Epidemiol Biomarkers Prev 26:837-844
Maturu, Paramahamsa; Jones, Devin; Ruteshouser, E Cristy et al. (2017) Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia 19:237-249
Huang, Le; Mokkapati, Sharada; Hu, Qianghua et al. (2016) Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with ?-Catenin Activation or Wt1 Ablation and Igf2 Upregulation. Neoplasia 18:71-81
Palculict, Timothy Blake; Ruteshouser, E Cristy; Fan, Yu et al. (2016) Identification of germline DICER1 mutations and loss of heterozygosity in familial Wilms tumour. J Med Genet 53:385-8
Liu, Changlu; Ma, Jianzhong; Amos, Christopher I (2015) Bayesian variable selection for hierarchical gene-environment and gene-gene interactions. Hum Genet 134:23-36
Mokkapati, Sharada; Niopek, Katharina; Huang, Le et al. (2014) ?-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. Cancer Res 74:4515-25
Quintás-Cardama, Alfonso; Post, Sean M; Solis, Luisa M et al. (2014) Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol 234:108-19
Maturu, Paramahamsa; Overwijk, Willem W; Hicks, John et al. (2014) Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Transl Oncol 7:484-92
Shahidul Makki, Mohammad; Cristy Ruteshouser, E; Huff, Vicki (2013) Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target. Exp Cell Res 319:612-22
Kaftanovskaya, Elena M; Neukirchner, Giselle; Huff, Vicki et al. (2013) Left-sided cryptorchidism in mice with Wilms' tumour 1 gene deletion in gubernaculum testis. J Pathol 230:39-47

Showing the most recent 10 out of 214 publications